While the use of methotrexate in RA is well supported by evidence, the same cannot be said for its use in psoriatic arthritis (PsA), an Australian led Cochrane Review has shown. The first systematic review of the evidence for the conventional synthetic DMARD (csDMARD) in PsA has found only low-quality evidence from one trial showing ...
First line use of bDMARDs over MTX in psoriatic arthritis: what Cochrane tells us
By Michael Woodhead
12 Feb 2019